A risk-based strategy for developing orthogonal analytical methods during R&D for high-risk pharmaceuticals. Grounded in ICH Q14 and USP <1220>, this proactive approach mitigates supply disruptions, method failures, and OOS investigations—transforming CMC into a resilient, lifecycle-ready system
16.01.26 07:50 PM - Comment(s)
